PDT FOR OESOPHAGEAL CANCER
WHAT TO EXPECT BEFORE, DURING, AND AFTER
Photodynamic therapy was the first cancer treatment to receive FDA approval for oesophageal cancer โ offering both palliative relief of swallowing difficulty and curative-intent treatment for early mucosal disease. Understanding the protocol, what happens in the days after treatment, and the photosensitivity precautions is essential for any patient considering this option.
analyticsAt a Glance
- check_circleFDA approved for obstructing oesophageal cancer and Barrett's oesophagus with HGD
- check_circlePhotofrin injection Day 1; endoscopic light delivery Day 3 (40โ50 hours later)
- check_circleDysphagia relief in 70โ85% of patients with obstructing tumours within 1โ2 weeks
- check_circleDebridement endoscopy 48 hours after light is essential โ removes tumour slough
When PDT Is Used for Oesophageal Cancer
Oesophageal cancer PDT serves different purposes depending on the stage and clinical context. Understanding which scenario applies to your case is the starting point for realistic expectations.
โPDT for oesophageal cancer has two very different roles: palliation for late-stage obstructing disease, and curative intent for early mucosal lesions. The expected outcomes, procedure details, and follow-up differ substantially between the two.โ
Palliative PDT: Relieving Dysphagia from Obstructing Tumours
For patients with advanced oesophageal cancer causing dysphagia (difficulty swallowing), PDT destroys tumour tissue in the oesophageal lumen, restoring the ability to eat and drink. This is a palliative (symptom-relieving) rather than curative treatment in advanced disease. PDT typically restores comfortable swallowing for 6โ12 weeks before re-treatment may be needed. Alternative palliative approaches include oesophageal stenting; PDT is preferred when the tumour is more circumferential or in locations where stenting is less suitable.
Curative-Intent PDT: Early Mucosal Cancer (T1a)
For superficial oesophageal cancer confined to the mucosa (T1a, no involvement of the submucosa, no lymph node involvement) in patients who cannot tolerate surgery, PDT offers curative-intent treatment. Complete local response rates of 60โ75% in selected patients. More commonly, endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) is preferred where feasible, but PDT fills an important role when endoscopic resection is not feasible.
Barrett's Oesophagus with High-Grade Dysplasia (HGD)
Barrett's oesophagus with high-grade dysplasia is a pre-cancerous condition that progresses to invasive cancer in a significant proportion of patients if untreated. Photofrin PDT is FDA-approved for ablating Barrett's HGD. It has largely been superseded by radiofrequency ablation (RFA) as the standard of care for Barrett's HGD at most centres โ but PDT remains an important option when RFA is not feasible or has failed.
The Complete Oesophageal PDT Timeline
A day-by-day timeline for a standard Photofrin PDT course for oesophageal cancer.
- 1
Day 0 (Pre-Treatment): Assessment
Endoscopic assessment confirming tumour extent and location. Review of CT staging and prior treatment history. Nutritional assessment โ many patients are malnourished from dysphagia; nutritional support (NG tube or PEG if severely malnourished) may be placed before starting. Photosensitivity precautions explained verbally and in writing. Consent signed.
- 2
Day 1: Photofrin Injection
Photofrin 2 mg/kg injected IV over 3โ5 minutes. Patient discharged home the same day in most cases. Strict light avoidance begins immediately from the moment of injection. Patient remains at home or in hospital under low-light conditions for the 40โ50 hour waiting period.
- 3
Day 3: Endoscopic Light Delivery (40โ50 Hours Post-Injection)
Under conscious sedation, endoscopy is performed. A diffuser fibre (for circumferential tumours) or a cylindrical fibre is passed through the endoscope and positioned at the tumour. Red laser light at 630 nm is delivered at 200โ400 J/cmยฒ. Procedure takes 15โ45 minutes. Patient discharged same day or stays overnight for observation.
- 4
Day 5: Debridement Endoscopy (48 Hours After Light)
A repeat endoscopy removes the necrotic tumour slough that has formed from PDT-induced cell death. This step is essential to prevent food bolus obstruction from the sloughed tissue. Most patients notice significant improvement in swallowing at this point. The lumen is gently irrigated and loose tissue removed.
- 5
Days 5โ14: Gradual Dietary Progression
After debridement, patients progress from liquids to soft foods to normal diet as swallowing improves. Dietitian support for nutritional rehabilitation. Some patients require one or two additional dilation sessions if residual tissue or early stricture formation occurs.
- 6
Weeks 1โ6: Full Photosensitivity Precautions
Strict sunlight and bright indoor light avoidance throughout. Eye protection (sunglasses indoors in bright environments). No sunscreen substitution โ protective clothing and light avoidance are the only reliable strategies. See PDT Photosensitivity Protection Guide for full detail.
- 7
4โ8 Weeks: First Response Assessment Endoscopy
Endoscopy assesses tumour response. For palliative cases: degree of luminal opening and dysphagia relief evaluated. For curative-intent cases: biopsy of the treated area confirms presence or absence of residual tumour. If residual disease is present, repeat PDT can be performed with a new drug injection.
Symptoms to Expect After Oesophageal PDT
Patients benefit from knowing what is normal and expected versus what should prompt urgent medical contact.
Dysphagia Worsening Before It Improves (Days 1โ5)
In the 48 hours between light delivery and debridement endoscopy, the treated tumour tissue becomes oedematous and necrotic โ temporarily making swallowing more difficult. This is expected. Complete liquids or saliva swallowing may be very difficult during this short window. After debridement, most patients notice clear improvement.
Chest Pain and Odynophagia (Painful Swallowing)
Inflammation in the treated oesophageal wall causes chest pain and pain with swallowing for 5โ14 days after PDT. Managed with liquid paracetamol, liquid NSAIDs, and if needed, opioid pain medication in liquid form. Pain should be improving by day 10โ14; persistent or worsening severe pain warrants medical review.
Low-Grade Fever (Days 3โ10)
Post-ablation fever from tumour necrosis is common for several days after PDT. Temperature typically 37.5โ38.5ยฐC. Managed with paracetamol. Fever above 38.5ยฐC, fever with rigors, or fever persisting beyond 10 days warrants investigation for infection.
Oesophageal Stricture (Weeks 4โ12)
PDT of the oesophageal wall causes scar formation as the tissue heals. Circumferential PDT (treating all the way around the oesophagus) has the highest stricture risk (20โ30%). Strictures present as recurrence of dysphagia weeks after initial improvement. Managed with endoscopic dilation โ typically 1โ3 sessions. The treating team should discuss stricture risk before treatment, particularly for circumferential lesions.
Expected Outcomes by Clinical Scenario
Published response rates and durability data for Photofrin PDT in oesophageal cancer and Barrett's oesophagus.
| Clinical Scenario | Response Rate | Duration of Benefit | Key Caveat |
|---|---|---|---|
| Palliation of obstructing oesophageal cancer | Dysphagia relief in 70โ85% of patients | Median 6โ12 weeks before re-treatment needed | Not curative; repeated treatments expected |
| Superficial oesophageal cancer (T1a, inoperable) | Complete response in 60โ75% of selected patients | Long-term disease control in complete responders; recurrence in others requires retreatment | Patient selection critical; ESD may be preferable if technically feasible |
| Barrett's oesophagus with high-grade dysplasia | Complete eradication of HGD in 75โ80% | Durable in most complete responders; surveillance continues lifelong | RFA now preferred at most centres; PDT reserved for RFA-failed or RFA-unsuitable cases |
| Squamous carcinoma in situ / severe dysplasia | Complete eradication in 70โ85% | Durable in complete responders | Endoscopic resection preferred when feasible; PDT for field treatment |
PDT vs Other Oesophageal Cancer Treatments
How PDT fits into the broader oesophageal cancer treatment landscape.
PDT Advantages
- No Systemic ToxicityUnlike chemotherapy: no nausea, hair loss, or myelosuppression from PDT itself.
- Preserves Oesophageal LumenDestroys tumour without removing the oesophagus โ function preserved in responders.
- RepeatableNo radiation dose limit โ PDT can be repeated multiple times as disease progresses or new lesions develop.
- Applicable to Long Segment DiseasePDT can treat longer segments of oesophageal disease than endoscopic mucosal resection.
- Outpatient-Feasible Core TreatmentDrug injection and light delivery each require only brief clinic/day-case visits.
When Alternatives Are Preferred
- Surgery for Resectable DiseaseOesophagectomy for surgically fit patients with T1b+ resectable disease remains the standard curative treatment.
- Endoscopic Resection for Early LesionsEMR or ESD for T1a lesions provides tissue diagnosis and curative excision in one procedure.
- Stenting for Rapid Dysphagia ReliefSelf-expanding metal stents provide faster dysphagia palliation than PDT โ PDT takes 5โ7 days to show effect; stenting is immediate.
- RFA for Barrett's HGDRadiofrequency ablation has become the standard for Barrett's HGD ablation โ better-tolerated and with high evidence base.
- Chemoradiation for Locally Advanced DiseaseDefinitive chemoradiation is the standard for non-surgical locally advanced oesophageal cancer.
Explore the PDT Knowledge Base
Related PDT topics and resources.
- What Is Photodynamic Therapy and How Does It Work?
- Photofrin (Porfimer Sodium): The Most Widely Approved Photosensitiser
- PDT Photosensitivity: The Complete Protection Guide
- Hyperthermia for Oesophageal Cancer โ China Programme
- Oesophageal Cancer โ Condition Page
- Photodynamic Therapy โ Full Treatment Page
Frequently Asked Questions
Common questions about PDT for oesophageal cancer.
About the Treatment
How quickly will my swallowing improve after oesophageal PDT?
Most patients notice significant improvement in swallowing difficulty within 5โ7 days โ typically after the debridement endoscopy on Day 5 removes the necrotic tumour tissue. The greatest functional improvement is usually evident at 1โ2 weeks. Some patients can return to near-normal diet within 2โ3 weeks; others continue to need soft or liquid diet for longer depending on the extent of treatment and any stricture formation. Dietitian support during recovery is strongly recommended.
Is the debridement endoscopy on Day 5 painful?
The debridement endoscopy is performed under conscious sedation โ the same sedation as the initial PDT light delivery. Patients do not feel the debridement itself. There may be mild discomfort from oesophageal inflammation during the scope passage. Most patients find the Day 5 endoscopy easier than the treatment endoscopy because the oedema from initial treatment has begun to subside.
What if my cancer involves the gastro-oesophageal junction or stomach?
PDT can be delivered endoscopically to tumours at the gastro-oesophageal junction (GEJ) as well as the oesophagus. GEJ tumours require specific fibre positioning to deliver light accurately to the tumour while minimising exposure to adjacent gastric mucosa. The procedure is technically similar to standard oesophageal PDT. Discuss the specific anatomy with your endoscopist at the planning stage.
Access and Eligibility
Can PDT be used alongside chemotherapy or radiotherapy for oesophageal cancer?
Yes. PDT can be combined with systemic therapies โ chemotherapy and immunotherapy continue as planned alongside PDT for local disease management. PDT should generally not be delivered concurrently with radiotherapy to the same field (the radiation sensitisation and healing effects complicate planning), but sequential use is common. Discuss timing with your oncology team.
Where is Photofrin oesophageal PDT available?
Photofrin oesophageal PDT is available at major academic medical centres in the US, Europe, Japan, China, and India with dedicated advanced endoscopy and PDT programmes. CancerFax can identify appropriate centres in China and India for international patients seeking access. Chinese centres with high oesophageal cancer volumes (oesophageal cancer is prevalent in China) have particularly extensive PDT experience.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Considering PDT for Oesophageal Cancer?
Upload your staging scans, endoscopy reports, and pathology. Our GI oncology team will assess whether Photofrin PDT is appropriate for your oesophageal cancer โ and identify the most experienced PDT centres for your case.
For informational purposes only. PDT suitability for oesophageal cancer requires evaluation by qualified GI oncology and advanced endoscopy specialists.